Oxford Nanopore | GenomeWeb

Oxford Nanopore

Oxford Nanopore Technologies was founded in 2005 to develop an electronic, single molecule sensing system based on nanopore science. The company now has more than 250 employees from multiple disciplines including nanopore science, molecular biology and applications, informatics, engineering, electronics, manufacturing and commercialization. Oxford Nanopore's instruments — MinIon, PromethIon, and GridIon are adaptable for the analysis of DNA, RNA, proteins, small molecules and other types of molecule.

Oxford Nanopore Facts

 

CEO: Gordon Sanghera

Website: www.nanoporetech.com

Ticker symbol: Privately held

Headquarters: Oxford, UK

Number of employees: 250+

The researchers noted that the results "highlight the great potential of nanopore sequencing to analyze broad microbial community trends."

Researchers funded in part by Oxford Nanopore recently published a study showing nanopores can detect proteins at the single-molecule level.

The company plans to use the new funding to expand into Asia, with a particular focus on China.

The researchers said that although improvements are needed for accurate basecalling, the MinIon is suitable for structural variant identification and haplotype phasing. 

The assembly of the agricultural pest Rhizoctonia solani genome was more contiguous and larger than previous short-read assemblies.

During a live webcast, CTO Clive Brown provided an update on the company's development plans and upcoming updates.

The next step to sequencing organisms found on the ISS or in space is to automate sample and library prep, according to a NASA microbiologist.

Researchers have shown that metagenomic sequencing on the MinIon can identify the pathogen and antimicrobial resistance profile of UTIs in several hours. 

The researchers demonstrated their Nanocall software on both E. coli and human DNA samples, showing it is comparable to an older version of the cloud-based software.

Pages

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.